Another option in our KIT of effective therapies for advanced melanoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survival.Oncology letters · 2021
   Article
2. Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?Frontiers in oncology · 2021
   Review
3. Repurposing Ponatinib as a Potent Agent againstTheranostics · 2019
   Article
4. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.Biomedicines · 2018
   Review
5. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.Oncotarget · 2017
   Article
6. [Molecular and immunohistochemical diagnostics in melanoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016
   Review
7. Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma.Melanoma management · 2015
   Review
8. Pathways and therapeutic targets in melanoma.Oncotarget · 2014
   Review
9. Imatinib: a breakthrough of targeted therapy in cancer.Chemotherapy research and practice · 2014
   Review

Corrections and comments

• Comment on
  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as